Fullcircle Wealth LLC Raises Position in Eli Lilly and Company $LLY

Fullcircle Wealth LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 12.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,385 shares of the company’s stock after buying an additional 151 shares during the period. Fullcircle Wealth LLC’s holdings in Eli Lilly and Company were worth $1,065,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at $35,000. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter valued at $40,000. Finally, TD Capital Management LLC raised its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $896.15 on Tuesday. The company has a market capitalization of $848.17 billion, a P/E ratio of 58.57, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a 50 day moving average of $784.74 and a 200 day moving average of $772.35. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Insiders Place Their Bets

In related news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. Guggenheim reiterated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Leerink Partners reiterated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.